New England Journal of Medicine vs European Heart Journal: Which Journal Should You Choose?

This comparison isn't about which journal is "better." It's about how broad the paper needs to be to justify a NEJM shot.

Many cardiology authors overestimate how often NEJM is the right answer. NEJM does publish cardiovascular medicine, but only the papers that escape the specialty box. European Heart Journal, by contrast, is built to reward work that matters deeply inside cardiovascular medicine, even if the paper wouldn't dominate general medicine conversation.

NEJM wins when the study is so consequential that it isn't just a cardiology story anymore.

That usually means:

• a major randomized trial with immediate treatment implications
• a result likely to reshape guidelines quickly
• a paper with hard endpoints and obvious clinical consequence
• a study that non-cardiologists will also care about

Think about the kinds of cardiovascular papers that become breakfast-table papers in hospitals. If your manuscript has that feel, NEJM is the natural first target.

NEJM also rewards tighter article architecture than many specialty journals. The journal wants a clean clinical story, not a long specialty debate. If the paper needs pages of cardiology-specific nuance to explain its value, that often works against a NEJM submission.

European Heart Journal wins when the paper is elite cardiology, but still cardiology.

That includes:

• large cardiovascular registries
• ESC-relevant clinical studies
• major prevention and risk-stratification papers
• imaging papers with direct diagnostic or prognostic consequence
• clinical trials that are important for cardiologists but may not command general-medicine readership

EHJ also has a distinct European Society of Cardiology identity. That matters. The journal is closely tied to ESC guideline culture, major European datasets, and international cardiovascular readership. A paper can be a perfect EHJ paper even if it would be too field-specific for NEJM.

This is why many cardiology manuscripts that are "too narrow" for NEJM aren't weak. They simply belong at the top of the specialty ladder instead of the top of the general-medicine ladder.

EHJ's submission guidance is more visibly tuned to field-specific article types and cardiology reporting. Original articles commonly run to around 4,000 words, while rapid communications are shorter. Structured abstracts and field-facing figure packages matter because cardiology readers often make decisions off the visual logic of the paper.

Large cardiovascular registries and population studies are often more naturally legible in EHJ than in NEJM. NEJM can publish a registry paper, but the standard is much harsher. The paper needs to feel broadly practice-changing, not just carefully executed.

A paper can be superb and still feel like a specialty-journal paper at NEJM. If the introduction, results, and discussion all assume a cardiology-native reader, that's usually a sign the manuscript may be pointed at the wrong journal.

• the trial or cohort result changes what clinicians across specialties will do
• the paper has hard outcomes and immediate management consequences
• the manuscript is short, clean, and clinically forceful
• you can explain the paper's importance without relying on field-specific background
• if accepted, the paper would plainly sit among the biggest medical stories of the month

In cardiovascular medicine, NEJM isn't the place for "very good." It's the place for papers people will immediately treat as field-shifting.

• the paper is top-tier cardiology but its first audience is still cardiologists
• the work has strong ESC, prevention, imaging, or registry relevance
• the manuscript benefits from specialty framing rather than stripped-down generalism
• the result matters at guideline and field level, even if it isn't a medicine-wide event
• you want a top cardiology journal where the readership, editors, and reviewers are living inside the field every day

That last point matters more than people admit. EHJ reviewers are more likely to appreciate a well-argued cardiology paper that would look too specialized to a general-medical editorial screen.

This is one of the cleaner cascades in medicine.

If NEJM rejects a cardiovascular paper because it's too specialty-specific, European Heart Journal is often a very logical next submission.

That path works especially well when:

• the science is strong
• the paper already reads like a field-leading cardiology paper
• the rejection was about breadth rather than methodological weakness

The reverse path is much less common. If a paper is already at EHJ and the discussion is about whether it should have gone to NEJM instead, the answer is usually that NEJM would only have been realistic if the manuscript had a much stronger broad-medicine claim from the start.

Authors often confuse prestige optimization with journal-fit optimization.

That leads to avoidable mistakes:

• sending excellent but field-specific cardiology work to NEJM
• burning a fast rejection cycle
• then submitting to EHJ only after losing time

A cleaner approach is to ask:

1. Is this really a general-medicine story?
2. Or is it a first-rate cardiology story?

If the honest answer is the second one, EHJ isn't settling. It's targeting the right top journal.

Is this paper so clinically important that it belongs in front of all medicine, not just cardiology?

Is this one of the strongest cardiovascular papers in its class, and does it matter enough for the global cardiology readership, especially the ESC-facing audience?

Those aren't the same question. A paper can fail the first and still pass the second easily.

Send to NEJM first if:

• the result is likely to be presented as a defining clinical trial
• the manuscript would still make sense to non-cardiologist readers
• the clinical consequence is immediate and hard to ignore

Send to European Heart Journal first if:

• the paper is an elite cardiology paper with obvious field-level consequence
• the European, guideline, imaging, prevention, or registry angle is central
• the paper would lose force if you tried to make it sound broader than it's

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.